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The interferons are an important first member of a family of biologic 
response-modifiers used in treating human malignancies. Activities 
associated with the interferons include inhibition of viral replication, 
influence on cellular protein production, direct antiproliferative effects, 
and a variety of modulatory effects on the immune response. These 
regulatory functions of interferon underlie the interest in its use as an 
anticancer agent. Alpha interferon is the most extensively studied 
interferon species. Although antitumor activity has been seen both in 
vitro and in vivo in some solid malignancies, the most impressive 
responses have occurrred in the hematoiogic malignancies. More than 
90 percent of patients with hairy ceil leukemia have a sustained 
recovery of their peripheral blood ceil counts with alpha interferon 
therapy. Approximately 50 percent of patients with low-grade non- 
Hodgkin’s iymphoma and cutaneous T ceil iymphoma demonstrate a 
response to alpha interferon. More than 80 percent of patients with 
chronic myeiogenous leukemia have a response to alpha interferon, 
and in one study, nearly half of the patients with response had com- 
plete suppression of the Philadelphia chromosome clone on at least 
one examination. Ongoing clinical trials are addressing such issues as 
optimal dosage, duration of alpha interferon therapy, and combinations 
of alpha interferon with other biologic agents, chemotherapy drugs, and 
radiation. 
Interferon was the term originally applied to a soluble factor that was 
recognized by its ability to induce interference against viral infection of 
chick chorioallantoic membrane by influenza A virus [I]. It has subse- 
quently been shown to be a family of closely related proteins and 
glycoproteins that, in addition to antiviral activity, are potent regulators of 
cellular function and structure and possess direct antiproliferative activi- 
ties. These latter properties underlie the current interest in interferon as 
an anticancer agent. 
Three major species of human interferon are recognized and designat- 
ed alpha interferon, beta interferon, and gamma interferon [2] (Table I). 
Alpha interferon is produced by leukocytes (B cells, T cells, null cells, and 
macrophages) upon exposure to B cell mitogens, viruses, foreign cells, 
or tumor cells. Beta interferon is produced by fibroblasts upon exposure 
to viruses or foreign nucleic acids. Gamma interferon is produced by T 
lymphocytes upon stimulation with T cell mitogens, specific antigens, or 
interleukin 2 [3]. By use of recombinant DNA techniques, complete 
nucleotide sequences for alpha, beta, and gamma interferons have been 
defined, and amino acid sequences have been derived. 
The genes recognized to code for alpha interferon have been assigned 
to chromosome 9 [4]. Sixteen distinct sequences for alpha interferon 
have been described [4]. Each is approximately 166 amino acids 
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TABLE I lnterferons in Clinical Use 
Type 
Subtype* 
(new nomenclature) Source 
Purity 











Roferon-A (Hoffman-La Roche) 
Recombinant alpha-D 
(IFN-alpha-D) 




Recombinant beta cys 
(rlFN-beta cys) 






Leukocytes from normal blood 
Lymphoblastoid (Namalva) cells 
in culture 
Transformed E. coli 
Transformed E. coli 
Transformed E. coli 
Transformed E. coli 
Fetal foreskin fibroblast 
in culture 
Transformed E. &Ii 
Transformed E. coli 
T lymphocytes from normal blood 












Arginine at position 23, 
deletion at position 44 when 
compared with other alpha subtypes 
Lysine at position 23, 
deletion at position 44 
29 variations from alpha-A 
Arginine at position 23, 
arginine at position 34 
Cysteine at position 17 
Serine at position 17 
* New nomenclature was proposed at a joint meeting of the World Health Organization and USAN council in May 1985. 
+ These crude preparations can be purified to near homogeneity (see text). 
in length with an additional 20 amino acid secretory 
peptide present on the amino-terminal end. The human 
genes differ by approximately 10 perdent in nucleotide 
sequence and 15 to 20 percent in amino acid sequence 
[5]. Two recombinant human interferons, alpha A and 
alpha D, make up more than 60 percent of interferons 
present after buffy coat stimulation and have been exten- 
sively studied [6]. Although they possess different antiviral 
and antiproliferative activity in vitro, similar in vivo effects 
on immune effector cells have been observed [6]. The 
alpha interferon used in the first human clinical trials was 
obtained from Sendai virus-stimulated buffy coat leuko- 
cytes and represented 1 percent purity ( lo6 units/mg 
protein)* [7]. Refinement in purification methods by use 
of high-performance liquid chromatography, two-dimen- 
sionat polyacrylamide gel electropharesis, and immuno- 
affinity chromatography has allowed purification to homo- 
geneity (1 O8 units/mg protein) [&IO]. The use of recom- 
binant DNA techniques with splicing of the alpha 
interferon gene into Escherichia coli has further allowed 
for pure single-species alpha interferon in larger quanti- 
ties. 
Unlike alpha interferon, only a single protein species 
has been identified for both beta and gamma interferon 
* Dne unit of interferon is roughly the amount that reduc- 
es viral replication in tissue culture by half. 
[5]. Beta interferon consists of 166 amino acids with 45 
percent homology of nucleotides and 29 percent amino 
acids compared with alpha interferon [5]. Gamma inter- 
feron consists of 146 amino acids and has approximately 
12 percent amino acid sequence homology compared 
with alpha interferon [ Ill. Gamma interferon may exist in 
biologic fluids in a dimeric form [ 121. 
Industrial-scale production of beta and gamma interfer- 
on has only recently been accomplished, and clinical trials 
are limited in number. Alpha interferon, however, has 
been extensively studied for the past decade in both basic 
science and clinical research, and it is among the most 
potent biologic agents ever administered to man. Al- 
though antitumor activity has been seen both in vitro and 
in vivo in some solid malignancies (breast cancer, renal 
ceil cancer, Kaposi’s sarcoma, bladder cancer, ovarian 
cancer, and melanoma) [13,14], the most impressive 
responses have occurred in the hematologic maiignan- 
ties. A review of these results and proposed mechanisms 
of action are presented. 
CLINICAL EXPERIENCE 
A summary of clinical trials using alpha k-tterferon for the 
hematologic matignancies is presented in Table II. Some 
reported trials have used highly.purified preparations (1 O8 
units/mg protein), whereas others have used crude prep- 
arations of alpha interferon (1 O6 units/mg protein). Impuri- 
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Response Rates Total 








Hairy cell leukemia? 
Non-Hodgkin’s lymphoma 
Low-grade 
Interinediate- and high-grade 
Hodgkin’s disease 
Cutaneous T cell lymphoma 
Chronic lyrnphocytic leukemia 
Multiple myeloma 
Chronic myelogenous leukemia 
Essential thrombocythemia 









30 6 42 
4 2 14 
0 2 0 
7 2 45 
12 18 
41r 26 
40 7 81 
0 75 
[ 60-643 Acute leukemia 62 0 195 31 
* Percent total response = complete responses + partial responses f number of evaluable patients. 
t Complete response means absence of hairy cells in the bone marrow and normalization of peripheral blood white cells, platelets, and 
erythrocytes. Partial response means a normalization of peripheral blood white cells, platelets, and erythrocyte counts and greater than 50 
percent reduction in hairy cells in the bone marrow. Minor response generally means improvement in hemoglobin to more than 10 g/dl or 
improvement in platelets to more than 100,000 cellslyl or improvement in neutrophils to more than 1,000 cells/yl. Percent total response 
for hairy cell leukemia includes minor responses. 
t Complete response and partial response not available from all trials, percent total response includes all responses. 
5 Most responses were of short duration. 
ties in-the latter include.albumin, transferrin, and additional 
lymphokines. Despite these contaminants, the toxicities 
and antitumor responses seen with both preparations 
have been similar. The major side effects have involved a 
flu-like illness (fever, chills, muscle aches, headache, 
gastrointestinal upset, and fatigue). The onset of fever is 
generally four to eight hours after administration with a 
duration of approximately 12 hours. With repeated admin- 
istration, tachyphylaxis to fever usually occurs, but fatigue 
and anorexia increase with dosage and duration of treat- 
ment and remain the usual dose-limiting toxicities. Other 
reported side effects include dose-related myelosuppres- 
sion, elevated transaminase concentrations, paresthe- 
sias, anosmia, somnolence, confusion, and impotence in 
men. One occurrence of interstitial nephritis has been 
reported [ 151, and elevation of hepatic transaminase lev- 
els was the dose-limiting toxicity in another study [ 161. 
All of these toxicities are reversible with cessation of 
drug. 
HAIRY CELL LEUKEMIA 
Hairy cell leukemia is a well-characterized lymphoprolif- 
erative disorder in which cells with lymphoid morphology 
and villous cytoplasmic projections infiltrate the bone 
marrow, blood, and reticuloendothelial system. It is of B 
cell origin and usually presents with cytopenias [ 171. The 
disease is often indolent, with a median age of onset 50 
years and a 5:l male-to-female ratio. Standard initial 
therapy is splenectomy, which often restores hematologic 
parameters to normal; however, most of these patients 
have a relapse weeks to years after splenectomy. Treat- 
ment of relapses has been generally poor with standard 
cytotoxic agents. Excellent responses were reported [ 181 
in seven patients with hairy cell leukemia (three complete 
and four partial responses) treated with crude alpha inter- 
feron. Similar data have been reported by a number of 
investigators using recombinant alpha interferon. Re- 
sponse rates have been comparable with recombinant 
preparations after therapy three times a week or daily with 
dosages ranging from 3 to 6 X IO6 units intramuscularly 
or subcutaneously [ 18-271. Although the initial report 
suggested that, complete responses were frequent, this 
has not been confirmed (of 158 responses reported, only 
22 were complete) [18-271. More important, however, is 
that virtually all of the patients with response demon- 
strated normalization of peripheral blood cell counts, 
which was maintained whiie they were receiving interfer- 
on therapy. Many of these patients had no prior therapy, 
including splenectomy. In patients with response, disease 
has not been reported to become refractory to alpha 
interferon; many patients have been followed for more 
than three years. In addition improvement in natural killer 
activity and immunologic surface markers parallels the 
hematologic recovery [24]. In a recent study [20], inter- 
feron treatment was discontinued in 25 patients after 12 
months of treatment. In eight of the 25 patients, a relapse 
occurred at a median of six months after cessation of 
treatment and resulted in reinduction of remission in five 
of the eight patients who have completed three months of 
therapy. Studies to assess low-dose (3 to 4 X lo6 units) 
compared with ultra-low-dose (0.3 to 0.4 X lo6 units) 
alpha interferon are currently underway. Phase Ill trials in 
which patients with newly diagnosed hairy cell leukemia 
are randomly assigned to undergo splenectomy or receive 
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alpha interferon treatment are also underway. Although 
hairy cell leukemia accounts for fewer than 2 percent of 
all cases of leukemia, its response to alpha interferon 
makes it an ideal disease to study the putative mecha- 
nisms of activity that are addressed next. 
NON-HOQGKIN’S LYMPHOMA AND HODGKIN’S 
DISEASE 
The histologic classification of non-Hodgkin’s lymphoma 
was recently reformulated from the commonly used Rap- 
paport system. On the basis of prognosis and morpholo- 
gy, the histologic types of malignant lymphoma have been 
grouped into low-, intermediate-, and high-grade malig- 
nancy under the Working Formulation [28]. Although 
many chemotherapy agents produce responses, low- 
grade non-Hodgkin’s lymphoma is not curable with cur- 
rently available treatment. This, in combination with the 
indolent nature of the disease, leads to multiple episodes 
of treatment and relapse; eventually the patient dies from 
unrelated causes, toxicity of therapy, progressive dis- 
ease, or emergence of a more aggressive histologic 
subtype. The low-grade non-Hodgkin’s lymphoma have 
shown responses to alpha interferon [29-351. Early re 
sults with crude alpha interferon preparations reported 
responses to alpha interferon in four of seven patients 
[29,30]. In the largest series reported to date [31], previ- 
ously treated patients received recombinant leukocyte 
alpha interferon at a dose of 50 X IO6 units/m* of body 
surface area intramuscularly three times a week. Thirteen 
responses were obtained (four complete and nine partial 
responses) among 24 evaluable patients, with a median 
duration of response of eight months. Alpha interferon in 
combination with standard cytotoxic agents is currently 
under investigation as first-line therapy. 
indolent clinical course. Effective therapies include topical 
mechlorethamine, psoralen plus ultraviolet light, total skin 
electron-beam irradiation, and systemic chemotherapy. 
Unfortunately, prolonged disease-free survival has been 
reported Only rarely with these therapies, and the best 
response rates for advanced disease are reported to be 
about 25 percent with short duration of response [37]. 
Responses in nine of 20 patients (two complete and 
seven partial) with advanced stages of disease refractory 
to prior therapy were observed [38] using recombinant 
alpha interferon at an intramuscular dosage of 50 X lo6 
units/m* body surface area three times a week. Re- 
sponses, defined as at least a 50 percent decrease in the 
sum of perpendicular measurements of malignant lesions 
lasting at least one month, occurred within four weeks of 
therapy and lasted three months to more than 25 months. 
Extracutaneous responses also occurred. A decrease in 
the size of large lesions by more than 90 percent oc- 
curred in a number of patients, suggesting that alpha 
interferon is the best single agent for cutaneous T cell 
lymphoma. 
CHRONIC LYMPHOCYllC LEUKEMIA 
Alpha interferon has shown less effectiveness in the 
intermediate- and high-grade lymphomas. Thirty-six pa- 
tients have been treated with both crude and recombinant 
alpha interferon, and five responses were reported 
[29,31,33,35,36]. Further study of alpha interferon in 
unfavorable non-Hodgkin’s lymphoma may be warranted 
to establish which patient subgroups might benefit from 
treatment. 
Eight patients with advanced refractory Hodgkin’s dis- 
ease have been treated with crude alpha interferon [33]. 
Only two brief minor responses were reported. In a recent 
study, however, with recombinant alpha interferon, ap- 
proximately 30 percent of patients with advanced refrac- 
tory Hodgkin’s disease have shown response (E. Bonnem, 
personal communication). 
Chronic lymphocytic leukemia is a hematolcgic malignan- 
cy characterized by proliferation and accumulation of 
relatively mature-appearing lymphocytes. Most patients 
have a clonal proliferation of B lymphocytes [39]. Chronic 
lymphocytic leukemia typically occurs in persons over 50 
years (median age 60 years) and affects men more than 
women at a ratio of 2: 1 [39]. The disease is usually stable 
over months to years, but transformation to a more ag- 
gressive disease state does occur. Alkylating agents, 
radiation therapy, and corticosteroids are commonly used 
to treat patients, although few data show that survival is 
substantially improved. In a number of early studies crude 
alpha interferon preparations were reported to be effec- 
tive in patients with advanced chronic lymphocytic leuke- 
mia [35,40,41]. In a phase II trial of recombinant alpha 
interferon, 18 patients were treated with both high-dose 
(50 X lo6 units/m* intramuscularly) and low-dose (5 X 
1 O6 units/m2 intramuscularly) recombinant alpha interfer- 
on three times a week [42]; only two brief responses 
were reported. Five patients appeared to have an accel- 
eration of disease while receiving recombinant alpha 
interferon. This low response rate was confirmed by a 
number of investigators [32,33,41,43,44]. It is in marked 
contrast to responses in patients with chemotherapy- 
refractory low-grade non-Hodgkin’s lymphoma and hairy 
cell leukemia as previously described, and the possible 
mechanism for this will be addressed. 
CUTANEOUS T CELL LYMPHOMA 
Cutaneous T cell lymphoma (mycosis fungoides and the 
Sezary syndrome) is a non-Hodgkin’s lymphoma charac- 
terized by a malignant proliferation of mature helper T 
lymphocytes that presents with skin infiltration and an 
MULTIPLE MYELOMA 
Multiple myeloma is a disease of uncontrolled prolifera- 
tion of malignant plasma cells in the marrow; it manifests 
clinically by tumor formation, osteolysis, hemopoiesis, 
hypogammaglobulinemia with a paraprotein ~OnOClOnal 
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spike, and renal disease. The mean age at the time of 
diagnosis is 62 years. Multiple myeloma responds initially 
to a variety of chemotherapeutic agents; however, once it 
becomes refractory to first-line therapy, further responses 
are difficult [45]. A number of trials with crude and recom- 
binant alpha interferon in patients with multiple myeloma 
have been reported [46-531. In a pilot study, four previ- 
ously untreated patients were treated daily with crude’ 
alpha interferon (3 X IO6 units intramuscularly). All pa- 
tients demonstrated durable responses (two complete and 
two partial) lasting three to 19 months [46]. This study 
was extended into a prospective randomized trial compar- 
ing crude alpha interferon (3 X 1 O6 units intramuscularly 
daily) with melphalan/prednisone on a six-week sched- 
ule. Fifty-three patients were allotted to melphalan- 
/prednisone and 62 patients to alpha interferon treatment. 
Total response rate was higher in the melphalan/predni- 
sone group (4 1 percent) than in the interferon group (14 
percent) (p <0.05) (response defined as a greater than 
50 percent decrease in paraprotein) [47]. 
Recombinant alpha interferon has been administered in 
a number of trials [49-531. Dosages ranged from 2 X lo6 
units/m* to 100 X 10” units/m* daily. Only 22 of 122 
previously treated patients had responses, compared with 
seven of 19 untreated patients. Of note is a recent obser- 
vation of synergy between alpha interferon and high-dose 
chlorambucil in patients with refractory myeloma [54]. 
Further trials of combination alkylating agent and interfer- 
on are ongoing. 
CHRONIC MYELOGENOUS LEUKEMIA 
Chronic myelogenous leukemia is a neoplastic disease 
characterized by clonal proliferation of a myeloid stem 
cell. A unique chromosomal translocation, the Philadel- 
phia chromosome, is present in about 90 percent of 
patients. The peak age of onset is 40 years. The clinical 
manifestation of the disease relates to accumulation of 
large numbers of immature and mature granulocytic cells 
in the blood and abdominal viscera. In most patients, the 
proliferation of the hematopoetic cells can be suppressed 
for one to four years with cytotoxic agents, but acute 
leukemia or a blast crisis develops in more than 80 
percent of patients [55]. In the acute phase, therapeutic 
agents including those useful in the treatment of acute 
leukemia are ineffective. Fifty-one patients with chronic 
myelogenous leukemia were treated with 3 to 9 X IO6 
units daily of crude (1 O6 units/mg protein) alpha interferon 
intramuscularly [56]. Forty-one of the patients demon- 
strated response to therapy, with complete (36 patients) 
or partial response (five patients) in the peripheral blood. 
Patients with response showed a gradual decrease of 
spleen size to normal and decrease in bone marrow 
cellularity. Suppression of the Philadelphia chromosome 
occurred in varying degrees in 20 of 5 1 patients and was 
complete in two patients. Successful lowering of platelet 
counts in nine patients (all previously treated) with severe 
symptomatic thrombocytosis has also been demonstrated 
[57] with crude alpha interferon. A recent study using 5 X 
1 O6 units/m* of recombinant alpha interferon daily dem- 
onstrated 13 hematologic remissions and one partial he- 
matologic remission among 17 patients [58]. In six of the 
patients with hematologic remission, there was complete 
suppression of the Philadelphia clone on at least one 
examination. Although these are very exciting data, they 
are preliminary and require confirmation. 
ESSENTIAL lHROMBOCYTHEMlA 
Essential thrombocythemia is a myeloproliferative dis- 
ease defined by a platelet count generally in excess of 
1 06/$, megakaryocyte hyperplasia in bone marrow, and 
absence of a predisposing cause (Le., Philadelphia chro- 
mosome, increased red cell mass, infection, or iron defi- 
ciency). Essential thrombocythemia usually appears be- 
tween the ages of 50 and 70 years. The major morbidity 
of the disease is bleeding and thrombosis with a 50 
percent 5-year survival rate. Several agents (32P, L-phe- 
nylalanine mustard, busulfan, uracil mustard, and hydroxy- 
urea) have been effective in lowering platelet counts. 
Recombinant alpha interferon has been administered to 
four previously untreated patients with essential thrombo- 
cythemia at a daily dosage of 5 to 10 X 1 O6 units 
intramuscularly for 30 days [59]. Platelet counts returned 
to normal in three of the four patients. Maintenance alpha 
interferon therapy twice a week was given after 30 days, 
and patients were followed for up to 80 days without 
relapse. Because no known leukemogenic potential ex- 
ists for alpha interferon, it may become a useful initial 
treatment of essential thrombocythemia. 
ACUTE LEUKEMIA 
Acute leukemia is a malignant stem cell disorder charac- 
terized by uncontrolled growth of poorly differentiated 
lymphoblasts. Early studies with crude alpha interferon 
were reported to produce responses in six of seven 
patients with acute lymphoblastic leukemia and two of 
three with acute nonlymphoblastic leukemia at daily dos- 
ages of 0.5 to 5 X lo6 units/kg intravenously for two 
weeks to two months. In phase I and II trials [62,63], 53 
patients were treated with partially pure lymphoblastoid 
alpha interferon (5 to 200 X IO6 units/m* daily for IO 
days). Five of 33 patients with leukemia experienced 
significant (80 to 99 percent) decreases in circulating 
blast counts, but bone marrow pathologic studies re- 
vealed only three patients with any degree of improve- 
ment in bone marrow infiltration (two transiently and one 
for three months). Recombinant alpha interferon (25 to 
100 X 1 O6 units daily for seven days) was administered to 
13 heavily pretreated patients with only two minimal 
responses [64]. Alpha interferon in high doses has had 
limited effectiveness for management of patients with 
acute leukemia. The role of lower dose alpha interferon 
has yet to be determined. 
ALPHA INTERFERON FOR HEMATOLOGIC MALIGNANCIES-ROTH and FOON 
November 1986 The American Journal of Medicine Volume 61 676 
ALPHA INTERFERON FOR HEMATOLOGIC MALIGNANCIES--ROTH and FOON 
TABLE III Cellular Events after Treatment with Alpha 
Interferon 
Intracellular protein changes 
Increased 2’-5’-oligoadenylate synthetase 
Increased protein kinase activity 
Direct antiproliferative effects 
Antiproliferative effect on tumor cell lines 
Antiproliferative effect on murine tumors in vivo 
Antiproliferative effects on transplanted tumors in nude mice 
lmmunomodulatory activities 
Enhancement (low dose) or suppression (high dose) of natural 
killer activity 
protein kinase capable of phosphorylating peptide eukary- 
otic initiation factor (elF-2 alpha) and ribosome-associ- 
ated protein PI [65,7 11. Recent observations suggest that 
the interferon-induced protein kinase is protein PI [71]. 
The net result of the kinase activation is the inhibition of 
peptide chain initiation. The exact role of these observa- 
tions in relation to anticancer activity remains undeter- 
mined. Preliminary data exist correlating the levels of 
induced 2’-5’-oligoadenylate synthetase with alpha inter- 
feron administration [72]; however, correlation with anti- 
tumor activity has not been made [73]. 
Augmentation of antibody dependent cellular cytotoxicity 
Enhancement of tumoricidal activity of macrophages 
Regulation of antibody production in B cells 
Enhancement of cytotoxic phase of mixed lymphocyte culture 
Depression of lymphoproliferative phase of mixed lymphocyte 
culture 
Increased expression of cell surface antigens, HLA-A, B, C, and 
B2 microglobulin 
Decreased oncogene expression 
ANTIPROLIFERATIVE EFFECT 
MODE OF ACTlON 
The effect of interferon at the cellular level is initiated by 
binding of the interferon molecule to a cell surface mem- 
brane receptor [65]. Competitive binding studies indicate 
that alpha and beta interferon interact with one cell sur- 
face receptor, whereas gamma interferon may interact 
with another receptor [65]. After binding to the cell sur- 
face membrane, human interferon is rapidly internalized 
and degraded [66]. Whether this internalization is required 
for the biologic responses to interferon has not been 
resolved. Similar to several polypeptide hormones and 
their target cells, a down-regulation of interferon recep- 
tors after exposure of cells to interferon occurs [66]. 
Alpha interferon has antiproliferative effect on some ma- 
lignant tumor cells. Dose-dependent in vitro inhibition of 
hernatologic cell lines using alpha interferon has been 
shown in BurkiWs lymphoma, lymphocytic lymphoma, 
acute myelogenous leukemia, chronic myelogenous leu- 
kemia, chronic lymphocy-tic leukemia, and multiple my- 
eloma [74-781. Interestingly, in comparative antiprolifer- 
ative studies, alpha interferon has shown a greater inhibi- 
tory effect in cells of hematopoietic origin than either beta 
or gamma interferon, using both crude and recombinant 
interferons [75,76,79]. Of note, noncycling tumor cells 
(Go-G,) appear to be a more sensitive target for the 
antiproliferative activity of human interferon [80,81]. 
Direct and indirect mechanisms of the anticancer activ- 
ity of interferon probably result from a number of different 
mechanisms, including induction of several intracellular 
proteins, enhancement of immune effector Cells, and 
changes in cellular surface structure (Table Ill). Two 
enzymes appear to play a major role in interferon activity. 
Treatment of cells in culture with interferon results in an 
increase in 2’-5’-oligoadenylate synthetase [67,68]; stud- 
ies suggest that this response represents the induction of 
a gene that is subject to control by interferon [69]. 2’-5’- 
oligoadenylate synthetase is capable of synthesizing a 
novel series of oligonucleotides, 2’-5’-oligoadenylates, in 
the presence of double-stranded RNA and ATP. These 
oligonucleotides range from 2 to 15 in length and are 
collectively referred to as 2’-5’A. 2’-5’A in turn activates 
a latent endoribonuclease that is capable of cleaving both 
viral and host RNA (messenger RNA and ribosomal RNA) 
effectively inhibiting transcription and translation 1651. 2’- 
5’A introduced into normal and neoplastic cells appears 
to inhibit both protein and DNA synthesis [70]. The second 
enzyme activated by exposure of cells to interferon is a 
Crude murine alpha interferon preparations have been 
shown to inhibit the growth of transplantable tumors of 
diverse origins (melanoma, friend leukemia, osteogenic 
sarcoma, Lewis lung, Ehrlich ascites) [82-851. In support 
of a direct antiproliferative effect are studies of transplant- 
ed human tumors in immunodeficient nude mice in which 
immunomodulatory effects of administered human alpha 
interferon are minimal [86,87]. Dose-dependent growth 
inhibition is observed in these models and persists only for 
the duration of treatment [86,87]. Evidence for direct 
antiproliferative effect in human trials is suggested in 
cutaneous T cell lymphoma. Four of 10 patients who had 
had a relapse while receiving a 10 percent maintenance 
dosage demonstrated responses after reescalation to 100 
percent dosage [37]. 
IMMUNOMODULATORY ACTIVITY 
lmmunomcdulatory activities of interferon are also of 
considerable interest and may possibly play a role in the 
anticancer effect. The first evidence of this indirect effect 
of interferon was demonstrated when mice inoculated 
with L1210 cells derived from an interferon-resistant 
clone were still protected by daily interferon treatment 
[88]. Because the resistant cells did not revert to interfer- 
on-sensitive cells in vivo, these experiments were inter- 
preted as suggesting that an antitumor effect was mediat- 
ed by the host, rather than by a direct effect on cell 
multiplication. Subsequently it has been shown that alpha 
interferon can enhance as well as suppress cell-mediated 
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and humoral immune responses that are believed to play 
an active role in tumor surveillance. 
Natural Killer Activity and Antibody-Dependent Cellular 
Cytotoxicity. Natural killer cells are a heterogeneous 
population of lymphocytes that are cytotoxic against sev- 
eral cell types and tumors in vitro [89]. Morphologically, 
human natural killer cells are identified as large granular 
lymphocytes. Direct evidence exists that natural killer 
cells inhibit in vivo tumor growth in animals; inhibition in 
humans has thus far been indirect and less consistent 
[go]. In in vitro systems, human natural killer cell cytolytic 
activation is consistently enhanced in the presence of 
both crude and pure alpha interferon [91-931. There is 
conflicting evidence regarding the natural killer cell-acti- 
vating effects of interferon in human therapy. Using both 
crude and pure alpha interferon, many clinical studies 
have documented interferon-induced increases in natural 
killer cell activity [94,95], whereas other investigators 
reported a lack of effect on natural killer activity or occa- 
sional depression of natural killer cytolytic activity by 
interferon [96,97]. To define the parameters governing 
this effect, purified lymphoblastoid interferon was given in 
one study in six dosages, ranging from IO5 to 3 X IO7 
units intramuscularly per week to cancer patients [98]. A 
negative correlation between the amount of interferon 
injected and the natural killer cell activity was found; 
cytolysis peaked at 24 hours after injection of 3 X lo6 
units (a three-fold increase). 
The exact mechanism by which interferon stimulates 
natural killer cell activity and by which natural killer cells 
lyse their targets is not fully understood. Some evidence 
suggests that interferon is able to induce differentiation of 
precursor cells into mature natural killer cells and to 
directly activate preexisting mature natural killer cells 
[99,100]. More recently, release of a natural killer cyto- 
toxic factor has been shown in supernatants of natural 
killer cells exposed to appropriate tumor target cells, and 
this cytotoxic factor is believed to be involved in natural 
killer-mediated cytolysis [ 10 11. Addition of alpha interfer- 
on to human lymphocytes results in augmentation of 
natural killer cytotoxic factor production [ 10 11. Further in 
vitro studies suggest that alpha interferon may be required 
for both the production of natural killer cytotoxic factor 
and the modulation of its lytic activity [ 1021. 
The lysis of specific antibody-coated target cells, 
known generally as antibody-dependent cellular cytotox- 
icky, has also been shown to be mediated by large 
granular lymphocytes [ 1031. Several studies have indicat- 
ed that both crude and purified alpha interferon prepara- 
tions are able to augment antibody-dependent cellular 
cytotoxicity responses mediated by human lymphocytes 
in vitro [91,104]. This increase also occurred against 
target cells resistant to natural killer activity [105]. More 
recently, it has been shown that pure alpha interferon 
enhances the antibody-dependent cellular cytotoxicity of 
human polymorphonuclear leukocytes against several he- 
matologic cell lines in vitro [ 1061. Interestingly, the effect 
was most pronounced when the IgG antibodies in the 
antibody-dependent cellular cytotoxicity reaction were 
present in suboptimal amounts; this suggests that interfer- 
on may play a role in initial in vivo immune response when 
IgG levels are still low [ 1061. Interferon may augment this 
activity by increasing the expression of FcG receptors on 
the lymphocyte cell surface, enhancing the binding of 
immunoglobulin-coated target cells [ 1071. Like the natural 
killer cell response in human trials, antibody-dependent 
cellular cytotoxicity response in patients receiving pure 
alpha interferon is variable [ 1081. 
Monocyte Function. Monocytes and macrophages are 
bone marrow-derived cells that have the capacity of 
phagocytosis and pinocytosis and more recently have 
been shown to be tumoricidal in vitro and in animal 
models [log]. Like natural killer cell activation, alpha 
interferon in vitro enhances tumoricidal monocyte func- 
tion [92,1 lo]. Unlike natural killer cell activation, human 
clinical trials with both crude and recombinant alpha inter- 
feron have shown consistent activation of monocyte tu- 
moricidal function [96,97]. The exact mechanism by 
which interferon activates monocy-tes in man remains 
unknown. Recent studies using recombinant interferon 
suggest that interferon acts as an inducer of macrophage 
Fc receptor-mediated phagocytosis [ 11 I]. Recombinant 
gamma interferon was significantly more potent than ei- 
ther alpha or beta interferon. Some studies suggest that 
gamma interferon is the major natural human lymphokine 
(known as the macrophage-activating factor) capable of 
inducing monocytemacrophage tumoricidal activity 
[112]. The role of activated macrophages in tumor sur- 
veillance or tumoricidal activity in humans is currently 
under investigation. 
B Lymphocytes. In vitro and in vivo studies of the effect 
of alpha interferon on immunoglobulin synthesis by B cells 
demonstrate that dosage and time of exposure are impor- 
tant. Pretreatment of human peripheral blood B lympho- 
cytes with both crude and pure alpha interferon before 
addition of mitogen enhances immunoglobulin production, 
but interferon treatment after exposure to mitogen sup- 
presses production [ 113,114]. Lower doses of alpha 
interferon enhance maturation of B cells, whereas sup- 
pression occurs at higher doses [I 15,116]. The en- 
hanced immunoglobulin production occurs even when 
peripheral blood lymphocytes are separated into T and B 
cell subpopulations before interferon administration, sug- 
gesting a direct effect on B cells [I 13,114]. The first in 
vivo evidence suggesting an effect of interferon on anti- 
body formation came from studies with mice [ 1171. Pre- 
liminary studies in human trials have demonstrated mini- 
mal increases of immunoglobulin secretion at 30 X lo6 
units, but not at other dosages [108]. Similar to the 
interferon effect on macrophages, gamma interferon has 
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been shown to be a more potent regulator of antibody 
response than alpha or beta interferon on an antiviral unit 
basis [ 1181. 
T Cells. T lymphocytes are the effector cells of cell- 
mediated immunity, and they perform a variety of func- 
tions including cellular cytotoxicit-y, helper and suppressor 
activity, and lymphokine production. The effect of interfer- 
on on T cells is complex: some phases of the T cell 
responses may be enhanced and others depressed. In 
vitro, alpha interferon enhances the cytotoxicity of the 
mixed lymphocyte cultures; however, proliferation is in- 
hibited [ 1191. Both inhibition and activation of T suppres- 
sor cells from mixed lymphocyte cultures have been 
observed [ 120,121]. In clinical trials, both crude and 
recombinant interferon has been shown to depress lym- 
phoproliferative response to mitogens and mixed lympho- 
cyte culture [96,97]. The importance of interferon’s ef- 
fects on T cells as it relates to antitumor effect is not 
known. 
Modulation of Cell Surface Antigens. Interferon induces 
a variety of changes in the cell surface including increases 
in the expression of Fc receptors on lymphocytes and 
macrophages that enhance tumoricidal activity 
[ 107,li 11. Consistent, increased expression of HLA anti- 
gens A, 6, and C and the HLA subunit Ba-microglobulin is 
observed with alpha, beta, and gamma interferon, both in 
vivo and in vitro [ 122,123]. Only gamma interferon has 
consistently increased expression of HLA-DR [ 1241; 
moreover, human gamma interferon, unlike alpha or beta, 
is able to increase expression of HLA-A, B, and C proteins 
on the cell surface at concentrations considerably lower 
than those necessary to induce an antiviral effect [125]. 
Because the HLA-DR system in humans appears to play a 
major role in the presentation of antigen for immune 
response [ 1261, gamma interferon may have a more 
important role in treatment directed at cell surface pro- 
teins than either alpha or beta interferon. 
Oncogene Expression. Neoplastic transformation of 
normal cells to malignant cells is now believed to be 
regulated by expression of cellular oncogenes. Rat fibro- 
blast cells exposed to the Rous sarcoma virus undergo 
malignant transformation resulting from the expression of 
the viral SIC oncogene. The product of this gene has been 
shown to be a tyrosine phosphokinase (pp60src) [ 1271 
that is capable of inducing this transformation. Treatment 
of Rous sarcoma virus-transformed rat cells with rat crude 
alpha interferon resulted in a 50 percent decrease in 
intracellular pp60src-associated protein kinase activity 
and a more normal growth pattern [ 1281. Moreover tritiat- 
ed leucine pulse labeling experiments showed that inter- 
feron worked by selectively reducing the synthesis of the 
src gene product [ 1281. 
before any inhibition of cell growth can be detected. 
Interestingly, no effect was seen on c-myc transcription 
rates, but rather an accelerated degradation of c-myc 
messenger RNA was noted (67 to 80 percent decrease in 
c-myc messenger RNA half-life) [ 1291. 
Effect of crude alpha interferon on oncogene expres- 
sion in peripheral blood cells from two patients with 
chronic myelogenous leukemia has also been studied 
[ 1301. Although the expression of several oncogenes @is, 
ras-Harvey, ras-Kirsten, and myc) remained unchanged 
during interferon therapy, a significant decrease in abl 
oncogene expression was detected within a few days 
after treatment was initiated in both patients. The results 
of these three studies suggest another mechanism by 
which interferon may inhibit tumor growth. 
MECHANISMS OF INTf%FERON ACTIVITY IN 
SPECIFIC DISEASES 
Hairy cell leukemia is the model disease for studying the 
effects of alpha interferon. Patients with hairy cell leuke- 
mia have a severe deficiency in natural killer cell activity. 
Recovery of natural killer activity has been reported 
[24,13 I] in most patients with hairy cell leukemia after 
alpha interferon therapy. The recovery of natural killer 
cells paralleled hematologic recovery. It remains unclear 
whether the natural killer cells played a direct role in 
hematologic recovery or were simply a byproduct of 
interferon-induced hematologic recovery. However, it 
was of interest that the low natural killer activity in the 
untreated cells was not really attributable to a relative 
deficiency or dilution of the effector cells because the 
percent of Leul l-positive cells, which identify the natural 
killer cells, was within the normal range. This suggests 
that alpha interferon activated these cells into functional 
effector cells [24]. In addition to natural killer cell recov- 
ery, improvement in the total numbers of T lymphocytes 
including both helper and suppressor populations and 
monocytes paralleled the improvement in the other hema- 
tologic parameters after alpha interferon therapy. 
Recombinant human alpha interferon has been shown 
to decrease accumulation of the cellular myc oncogene 
messenger RNA in the Daudi cell line (Burkitt’s lympho- 
ma) [ 1291. The effect is dose-dependent and occurs 
Hairy cell leukemia and low-grade lymphomas are both 
indolent diseases of B cell origin. Alpha interferon has a 
high degree of activity in both diseases [18-27,29-351. 
The lack of responsiveness of another indolent B cell 
malignancy, chronic lymphocytic leukemia, has as yet 
been unexplained [35,40-441. A comparison of binding 
of iodinated recombinant alpha interferon to normal pe 
ripheral blood mononuclear cells, hairy cell leukemia 
cells, and chronic lymphocytic leukemia cells demon- 
strated that hairy cells bound approximately twice as 
much iodinated interferon as chronic lymphocytic leuke- 
mia and normal cells; however, the hairy cells had twice 
the surface area, which may explain the greater number 
of receptors [ 1321. 
Alpha interferon has been reported to induce cell sur- 
face and intracellular proteins in patients with hairy cell 
leukemia [ 1331. Autoradiographic analysis of onedimen- 
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sional polyactylamide gels showed induction of at least six 
proteins in nine patients treated with recombinant alpha 
interferon. Overall protein synthesis was not significantly 
altered. Some of these proteins were in the cell mem- 
brane, leading the investigators to suggest that interferon 
induces a protein signal in the hairy cell enabling their 
destruction [ 1331. 
Most recently Raldini and coworkers [134] isolated 
hairy cells from the spleens of previously untreated pa- 
tients and cultured them in the presence of recombinant 
human alpha interferon. Monoclonal antibody surface 
marker studies revealed a significant enhancement of 
class II HLA antigen (HLA-DR). Because HLA antigens 
have been shown to be involved in cell-mediated cytotox- 
icity [ 1261, they speculated that selective enhancement of 
class II HLA antigen may be another in vivo therapeutic 
mechanism of alpha interferon. 
CONCLUSIONS 
The importance of interferon as a direct antitumor agent 
or a biologic response-modifier remains an unanswered 
question in the treatment of malignant diseases. Although 
it is clear that interferon will not be effective in most 
cancers, we have reviewed interferon’s effectiveness in 
managing some of the hematologic malignancies. Even in 
these diseases, the optimal dose of interferon is uncer- 
tain. High doses may have greater direct antiproliferative 
activity, yet they may also suppress the immune system. 
Low doses may be more effective in enhancing the im- 
mune system. Interferon’s role as a first-line treatment or 
in combination with standard cytotoxic drugs or other 
biologic response-modifiers is an area of ongoing re- 
search. Regardless of the eventual role of alpha interferon 
in the treatment of cancer, it is an important first member 
of a family of biologic response-modifiers used in treating 
human malignancies. 
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